Beta-bloccanti e sistema cardiovascolare: Attuali acquisizioni e controversie

Translated title of the contribution: Present trends and controversies in the use of beta-blockers in cardiovascular diseases

Roberto Spoladore, Gabriele Fragasso, Claudia Montanaro, Francesco Maranta, Camilla Torlasco, Stefano Gerosa, Alberto Margonato

Research output: Contribution to journalArticle

Abstract

In this paper we summarize present trends and controversies in the use of beta-blockers in cardiovascular diseases. Beta-blockers are catecolamine competitive inhibitors and act through alpha and beta adrenergic receptors blockade. Different agents have a dose-dependent affinity for different beta adrenergic receptors (beta 1, beta 2, beta 3) which is less with higher doses. The most important therapeutic effects of beta-blockers are on cardiovascular system, where they act as negative chronotropic and inotropic agents, lowering cardiac work and improving oxygen demand/supply ratio. Clinical indications are numerous. For their anti-ischemic activity beta-blockers are used as anti-anginal drugs and in acute and previous myocardial infarction for preventing total and cardiovascular mortality. Combined use of beta-blockers and ACE inhibitors slows down heart failure progression and reduces cardiovascular mortality. Beta-blockers are useful in treating focal atrial tachycardia and supra ventricular paroxysmal tachycardia, by reducing sinus node automaticity and delay atrio-ventricular conduction; they also prevent sudden cardiac death and ventricular tachycardia associated with increased sympathetic activity. There is no indication in treating primary non-complicated hypertension with beta-blockers as first-line drugs. Different metabolic effects of selective and non-selective beta-blockers are actually debated. In conclusion, betablockers have indication in the treatment of many cardiovascular diseases. Further studies are needed for better understanding the differences in cardiac and peripheral beta-blockers effects depending on their selectivity.

Original languageItalian
Pages (from-to)429-441
Number of pages13
JournalRecenti Progressi in Medicina
Volume101
Issue number11
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Ventricular Tachycardia
Adrenergic beta-1 Receptors
Cardiovascular Diseases
Paroxysmal Tachycardia
Receptors, Adrenergic, alpha
Sinoatrial Node
Mortality
Receptors, Adrenergic, beta
Sudden Cardiac Death
Therapeutic Uses
Cardiovascular System
Angiotensin-Converting Enzyme Inhibitors
Tachycardia
Pharmaceutical Preparations
Heart Failure
Myocardial Infarction
Oxygen
Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Beta-bloccanti e sistema cardiovascolare : Attuali acquisizioni e controversie. / Spoladore, Roberto; Fragasso, Gabriele; Montanaro, Claudia; Maranta, Francesco; Torlasco, Camilla; Gerosa, Stefano; Margonato, Alberto.

In: Recenti Progressi in Medicina, Vol. 101, No. 11, 11.2010, p. 429-441.

Research output: Contribution to journalArticle

Spoladore, Roberto ; Fragasso, Gabriele ; Montanaro, Claudia ; Maranta, Francesco ; Torlasco, Camilla ; Gerosa, Stefano ; Margonato, Alberto. / Beta-bloccanti e sistema cardiovascolare : Attuali acquisizioni e controversie. In: Recenti Progressi in Medicina. 2010 ; Vol. 101, No. 11. pp. 429-441.
@article{1228a1cdf0f94548b523adf37e491eff,
title = "Beta-bloccanti e sistema cardiovascolare: Attuali acquisizioni e controversie",
abstract = "In this paper we summarize present trends and controversies in the use of beta-blockers in cardiovascular diseases. Beta-blockers are catecolamine competitive inhibitors and act through alpha and beta adrenergic receptors blockade. Different agents have a dose-dependent affinity for different beta adrenergic receptors (beta 1, beta 2, beta 3) which is less with higher doses. The most important therapeutic effects of beta-blockers are on cardiovascular system, where they act as negative chronotropic and inotropic agents, lowering cardiac work and improving oxygen demand/supply ratio. Clinical indications are numerous. For their anti-ischemic activity beta-blockers are used as anti-anginal drugs and in acute and previous myocardial infarction for preventing total and cardiovascular mortality. Combined use of beta-blockers and ACE inhibitors slows down heart failure progression and reduces cardiovascular mortality. Beta-blockers are useful in treating focal atrial tachycardia and supra ventricular paroxysmal tachycardia, by reducing sinus node automaticity and delay atrio-ventricular conduction; they also prevent sudden cardiac death and ventricular tachycardia associated with increased sympathetic activity. There is no indication in treating primary non-complicated hypertension with beta-blockers as first-line drugs. Different metabolic effects of selective and non-selective beta-blockers are actually debated. In conclusion, betablockers have indication in the treatment of many cardiovascular diseases. Further studies are needed for better understanding the differences in cardiac and peripheral beta-blockers effects depending on their selectivity.",
keywords = "Atrial tachycardia, Beta-blockers, Cardiovascular mortality, Heart failure, Hypertension, Insulin resistance syndrome, Myocardial infarction, Ventricular tachycardia",
author = "Roberto Spoladore and Gabriele Fragasso and Claudia Montanaro and Francesco Maranta and Camilla Torlasco and Stefano Gerosa and Alberto Margonato",
year = "2010",
month = "11",
doi = "10.1701/526.6286",
language = "Italian",
volume = "101",
pages = "429--441",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "11",

}

TY - JOUR

T1 - Beta-bloccanti e sistema cardiovascolare

T2 - Attuali acquisizioni e controversie

AU - Spoladore, Roberto

AU - Fragasso, Gabriele

AU - Montanaro, Claudia

AU - Maranta, Francesco

AU - Torlasco, Camilla

AU - Gerosa, Stefano

AU - Margonato, Alberto

PY - 2010/11

Y1 - 2010/11

N2 - In this paper we summarize present trends and controversies in the use of beta-blockers in cardiovascular diseases. Beta-blockers are catecolamine competitive inhibitors and act through alpha and beta adrenergic receptors blockade. Different agents have a dose-dependent affinity for different beta adrenergic receptors (beta 1, beta 2, beta 3) which is less with higher doses. The most important therapeutic effects of beta-blockers are on cardiovascular system, where they act as negative chronotropic and inotropic agents, lowering cardiac work and improving oxygen demand/supply ratio. Clinical indications are numerous. For their anti-ischemic activity beta-blockers are used as anti-anginal drugs and in acute and previous myocardial infarction for preventing total and cardiovascular mortality. Combined use of beta-blockers and ACE inhibitors slows down heart failure progression and reduces cardiovascular mortality. Beta-blockers are useful in treating focal atrial tachycardia and supra ventricular paroxysmal tachycardia, by reducing sinus node automaticity and delay atrio-ventricular conduction; they also prevent sudden cardiac death and ventricular tachycardia associated with increased sympathetic activity. There is no indication in treating primary non-complicated hypertension with beta-blockers as first-line drugs. Different metabolic effects of selective and non-selective beta-blockers are actually debated. In conclusion, betablockers have indication in the treatment of many cardiovascular diseases. Further studies are needed for better understanding the differences in cardiac and peripheral beta-blockers effects depending on their selectivity.

AB - In this paper we summarize present trends and controversies in the use of beta-blockers in cardiovascular diseases. Beta-blockers are catecolamine competitive inhibitors and act through alpha and beta adrenergic receptors blockade. Different agents have a dose-dependent affinity for different beta adrenergic receptors (beta 1, beta 2, beta 3) which is less with higher doses. The most important therapeutic effects of beta-blockers are on cardiovascular system, where they act as negative chronotropic and inotropic agents, lowering cardiac work and improving oxygen demand/supply ratio. Clinical indications are numerous. For their anti-ischemic activity beta-blockers are used as anti-anginal drugs and in acute and previous myocardial infarction for preventing total and cardiovascular mortality. Combined use of beta-blockers and ACE inhibitors slows down heart failure progression and reduces cardiovascular mortality. Beta-blockers are useful in treating focal atrial tachycardia and supra ventricular paroxysmal tachycardia, by reducing sinus node automaticity and delay atrio-ventricular conduction; they also prevent sudden cardiac death and ventricular tachycardia associated with increased sympathetic activity. There is no indication in treating primary non-complicated hypertension with beta-blockers as first-line drugs. Different metabolic effects of selective and non-selective beta-blockers are actually debated. In conclusion, betablockers have indication in the treatment of many cardiovascular diseases. Further studies are needed for better understanding the differences in cardiac and peripheral beta-blockers effects depending on their selectivity.

KW - Atrial tachycardia

KW - Beta-blockers

KW - Cardiovascular mortality

KW - Heart failure

KW - Hypertension

KW - Insulin resistance syndrome

KW - Myocardial infarction

KW - Ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=78751500726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751500726&partnerID=8YFLogxK

U2 - 10.1701/526.6286

DO - 10.1701/526.6286

M3 - Articolo

C2 - 21197763

AN - SCOPUS:78751500726

VL - 101

SP - 429

EP - 441

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 11

ER -